Search Structure Search
wx_img
Inquiry Form
  1. Home
  2. SENS-401

SENS-401

Sensorion announced it has met the primary endpoint for its Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation. SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss (SSNHL). It is aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss.

Methyl 5-chloro-2-hydroxybenzoate
Methyl 5-chloro-2-hydroxybenzoate
CM157726
4068-78-4
2-(carboxymethoxy)-5-chlorobenzoic acid
2-(carboxymethoxy)-5-chlorobenzoic acid
CM1075465
334758-22-4
6-Chloro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxylic acid
6-Chloro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxylic acid
CM634285
123040-45-9
1-Azabicyclo[2.2.2]octan-3-amine, (3R)-
1-Azabicyclo[2.2.2]octan-3-amine, (3R)-
CM431540
123536-15-2